Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Glioblastoma | Research

LINC00606 promotes glioblastoma progression through sponge miR-486-3p and interaction with ATP11B

Authors: Naijun Dong, Wenxin Qi, Lingling Wu, Jie Li, Xueqi Zhang, Hao Wu, Wen Zhang, Jiawen Jiang, Shibo Zhang, Wenjun Fu, Qian Liu, Guandong Qi, Lukai Wang, Yanyuan Lu, Jingyi Luo, Yanyan Kong, Yihao Liu, Robert Chunhua Zhao, Jiao Wang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Background

LncRNAs regulate tumorigenesis and development in a variety of cancers. We substantiate for the first time that LINC00606 is considerably expressed in glioblastoma (GBM) patient specimens and is linked with adverse prognosis. This suggests that LINC00606 may have the potential to regulate glioma genesis and progression, and that the biological functions and molecular mechanisms of LINC00606 in GBM remain largely unknown.

Methods

The expression of LINC00606 and ATP11B in glioma and normal brain tissues was evaluated by qPCR, and the biological functions of the LINC00606/miR-486-3p/TCF12/ATP11B axis in GBM were verified through a series of in vitro and in vivo experiments. The molecular mechanism of LINC00606 was elucidated by immunoblotting, FISH, RNA pulldown, CHIP-qPCR, and a dual-luciferase reporter assay.

Results

We demonstrated that LINC00606 promotes glioma cell proliferation, clonal expansion and migration, while reducing apoptosis levels. Mechanistically, on the one hand, LINC00606 can sponge miR-486-3p; the target gene TCF12 of miR-486-3p affects the transcriptional initiation of LINC00606, PTEN and KLLN. On the other hand, it can also regulate the PI3K/AKT signaling pathway to mediate glioma cell proliferation, migration and apoptosis by binding to ATP11B protein.

Conclusions

Overall, the LINC00606/miR-486-3p/TCF12/ATP11B axis is involved in the regulation of GBM progression and plays a role in tumor regulation at transcriptional and post-transcriptional levels primarily through LINC00606 sponging miR-486-3p and targeted binding to ATP11B. Therefore, our research on the regulatory network LINC00606 could be a novel therapeutic strategy for the treatment of GBM.

Graphical Abstract

LINC00606 is highly expressed in GBM patients with carcinogenic function and correlated with poor prognosis. LINC00606 regulates glioblastoma progression by sponging miR-486-3p and interacting with ATP11B.
Appendix
Available only for authorised users
Literature
1.
Barthel L, Hadamitzky M, Dammann P, Schedlowski M, Sure U, Thakur BK, et al. Glioma: molecular signature and crossroads with tumor microenvironment. Cancer Metastasis Rev. 2022;41(1):53–75.CrossRefPubMed
2.
Cavanagh R, Baquain S, Oz UC, Sikder A, ElSherbeny A, Alexander C, et al. Pro-drug nanoparticles as synergistic drug combination carriers for IDH1-WT glioblastoma. Neuro Oncol. 2023;25(Supplement_3):iii1-iii.CrossRef
3.
Chen P, Lu Y, He B, Xie T, Yan C, Liu T, et al. Rab32 promotes glioblastoma migration and invasion via regulation of ERK/Drp1-mediated mitochondrial fission. Cell Death Dis. 2023;14(3):198.CrossRefPubMedPubMedCentral
4.
De Silva MI, Stringer BW, Bardy C. Neuronal and tumourigenic boundaries of glioblastoma plasticity. Trends Cancer. 2023;9(3):223–36.CrossRefPubMed
5.
Huang-Hobbs E, Cheng YT, Ko Y, Luna-Figueroa E, Lozzi B, Taylor KR, et al. Remote neuronal activity drives glioma progression through SEMA4F. Nature. 2023;619(7971):844–50.CrossRefPubMedPubMedCentral
6.
Watson DC, Bayik D, Storevik S, Moreino SS, Sprowls SA, Han J, et al. GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity. Nat Cancer. 2023;4(5):648–64.CrossRefPubMedPubMedCentral
7.
Liu J, Tao X, Zhu Y, Li C, Ruan K, Diaz-Perez Z, et al. NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis. Elife. 2021;10:e70046.CrossRefPubMedPubMedCentral
8.
Hadian K, Stockwell BR. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat Rev Drug Discov. 2023;22(9):723–42.CrossRefPubMed
9.
Fesenko I, Shabalina SA, Mamaeva A, Knyazev A, Glushkevich A, Lyapina I, et al. A vast pool of lineage-specific microproteins encoded by long non-coding RNAs in plants. Nucleic Acids Res. 2021;49(18):10328–46.CrossRefPubMedPubMedCentral
10.
Nemeth K, Bayraktar R, Ferracin M, Calin GA. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet. 2024;25(3):211–32.CrossRefPubMed
11.
12.
Zhang Y, Dong X, Guo X, Li C, Fan Y, Liu P, et al. LncRNA-BC069792 suppresses tumor progression by targeting KCNQ4 in breast cancer. Mol Cancer. 2023;22(1):41.CrossRefPubMedPubMedCentral
13.
Wheeler BD, Gagnon JD, Zhu WS, Muñoz-Sandoval P, Wong SK, Simeonov DS, et al. The lncRNA Malat1 inhibits miR-15/16 to enhance cytotoxic T cell activation and memory cell formation. Elife. 2023;12:RP87900.CrossRefPubMedPubMedCentral
14.
Nandwani A, Rathore S, Datta M. LncRNAs in cancer: Regulatory and therapeutic implications. Cancer Lett. 2021;501:162–71.CrossRefPubMed
15.
Chen L, Zhang C, Ma W, Huang J, Zhao Y, Liu H. METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. Nucleic Acids Res. 2022;50(20):11619–34.CrossRefPubMedPubMedCentral
16.
Guo K, Qian K, Shi Y, Sun T, Wang Z. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis. 2021;12(12):1097.CrossRefPubMedPubMedCentral
17.
Zhou Y, Shao Y, Hu W, Zhang J, Shi Y, Kong X, et al. A novel long noncoding RNA SP100-AS1 induces radioresistance of colorectal cancer via sponging miR-622 and stabilizing ATG3. Cell Death Differ. 2023;30(1):111–24.CrossRefPubMed
18.
Qin G, Tu X, Li H, Cao P, Chen X, Song J, et al. Long noncoding RNA p53-stabilizing and activating RNA promotes p53 signaling by inhibiting heterogeneous nuclear ribonucleoprotein K deSUMOylation and suppresses hepatocellular carcinoma. Hepatology. 2020;71(1):112–29.CrossRefPubMed
19.
Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou A, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)A reader YTHDF3. Mol Cancer. 2019;18(1):143.CrossRefPubMedPubMedCentral
20.
Yuan K, Lan J, Xu L, Feng X, Liao H, Xie K, et al. Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling. Mol Cancer. 2022;21(1):105.CrossRefPubMedPubMedCentral
21.
22.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.CrossRefPubMedPubMedCentral
23.
Horbinski C, Berger T, Packer RJ, Wen PY. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol. 2022;18(9):515–29.CrossRefPubMed
24.
Wang J, Li W, Zhou F, Feng R, Wang F, Zhang S, et al. ATP11B deficiency leads to impairment of hippocampal synaptic plasticity. J Mol Cell Biol. 2019;11(8):688–702.CrossRefPubMedPubMedCentral
25.
Wang J, Molday LL, Hii T, Coleman JA, Wen T, Andersen JP, et al. Proteomic Analysis and Functional Characterization of P4-ATPase Phospholipid Flippases from Murine Tissues. Sci Rep. 2018;8(1):10795.CrossRefPubMedPubMedCentral
26.
Wang J, Qi W, Shi H, Huang L, Ning F, Wang F, et al. MiR-4763-3p targeting RASD2as a potential biomarker and therapeutic target for Schizophrenia. Aging Dis. 2022;13(4):1278–92.CrossRefPubMedPubMedCentral
27.
Liu Y, Wang X, Zhu Y, Cao Y, Wang L, Li F, et al. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression. Clin Transl Med. 2022;12(2):e654.CrossRefPubMedPubMedCentral
28.
Zhang Y, Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat Commun. 2022;13(1):2669.CrossRefPubMedPubMedCentral
29.
Yang J, Qiu Q, Qian X, Yi J, Jiao Y, Yu M, et al. Long noncoding RNA LCAT1 functions as a ceRNA to regulate RAC1 function by sponging miR-4715-5p in lung cancer. Mol Cancer. 2019;18(1):171.CrossRefPubMedPubMedCentral
30.
Chou ST, Peng HY, Mo KC, Hsu YM, Wu GH, Hsiao JR, et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1. J Exp Clin Cancer Res. 2019;38(1):281.CrossRefPubMedPubMedCentral
31.
Jiang M, Li X, Quan X, Yang X, Zheng C, Hao X, et al. MiR-486 as an effective biomarker in cancer diagnosis and prognosis: a systematic review and meta-analysis. Oncotarget. 2018;9(17):13948–58.CrossRefPubMedPubMedCentral
32.
Plaisier CL, O’Brien S, Bernard B, Reynolds S, Simon Z, Toledo CM, et al. Causal mechanistic regulatory network for glioblastoma deciphered using systems genetics network analysis. Cell Syst. 2016;3(2):172–86.CrossRefPubMedPubMedCentral
33.
Vibert J, Saulnier O, Collin C, Petit F, Borgman KJE, Vigneau J, et al. Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions. Mol Cell. 2022;82(13):2458–71 e9.CrossRefPubMed
34.
Yang J, Zhang L, Jiang Z, Ge C, Zhao F, Jiang J, et al. TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression. Theranostics. 2019;9(20):5810–27.CrossRefPubMedPubMedCentral
35.
Selvakumar SC, Preethi KA, Sekar D. MicroRNAs as important players in regulating cancer through PTEN/PI3K/AKT signalling pathways. Biochim Biophys Acta Rev Cancer. 2023;1878(3):188904.CrossRefPubMed
36.
Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38(1):81.CrossRefPubMedPubMedCentral
37.
38.
Hu J, Huang H, Xi Z, Ma S, Ming J, Dong F, et al. LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis. Cell Death Dis. 2022;13(9):800.CrossRefPubMedPubMedCentral
39.
Liu Y, Shi M, He X, Cao Y, Liu P, Li F, et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022;15(1):52.CrossRefPubMedPubMedCentral
40.
Xu J, Su SM, Zhang X, Chan UI, Adhav R, Shu X, et al. ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine. J Clin Invest. 2022;132(5):e149473.CrossRefPubMedPubMedCentral
41.
Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, et al. (18)F-FET PET imaging in differentiating glioma progression from treatment-related changes: a single-center experience. J Nucl Med. 2020;61(4):505–11.CrossRefPubMed
42.
Haubold J, Demircioglu A, Gratz M, Glas M, Wrede K, Sure U, et al. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric (18)F-FET PET-MRI and MR fingerprinting. Eur J Nucl Med Mol Imaging. 2020;47(6):1435–45.CrossRefPubMed
43.
Kumari S, Gupta R, Ambasta RK, Kumar P. Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy. Biochim Biophys Acta Rev Cancer. 2023;1878(4):188913.CrossRefPubMed
44.
45.
Hou G, Zhao X, Li L, Yang Q, Liu X, Huang C, et al. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res. 2021;49(5):2859–77.CrossRefPubMedPubMedCentral
46.
Chen Y, Lin Y, Shu Y, He J, Gao W. Interaction between N(6)-methyladenosine (m(6)A) modification and noncoding RNAs in cancer. Mol Cancer. 2020;19(1):94.CrossRefPubMedPubMedCentral
47.
Yang Q, Wang M, Xu J, Yu D, Li Y, Chen Y, et al. LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling. Mol Cancer. 2023;22(1):122.CrossRefPubMedPubMedCentral
48.
Pan J, Fang S, Tian H, Zhou C, Zhao X, Tian H, et al. lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling. Mol Cancer. 2020;19(1):9.CrossRefPubMedPubMedCentral
49.
Zhang X, Niu W, Mu M, Hu S, Niu C. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop. J Exp Clin Cancer Res. 2020;39(1):196.CrossRefPubMedPubMedCentral
50.
Xu L, Wu Q, Yan H, Shu C, Fan W, Tong X, et al. Long noncoding RNA KB-1460A1.5 inhibits glioma tumorigenesis via miR-130a-3p/TSC1/mTOR/YY1 feedback loop. Cancer Lett. 2022;525:33–45.CrossRefPubMed
51.
Hallal S, EbrahimKhani S, Wei H, Lee MYT, Sim HW, Sy J, et al. Deep sequencing of small RNAs from neurosurgical extracellular vesicles substantiates miR-486–3p as a circulating biomarker that distinguishes glioblastoma from lower-grade astrocytoma patients. Int J Mol Sci. 2020;21(14):4954.CrossRefPubMedPubMedCentral
52.
Wu H, Li X, Zhang T, Zhang G, Chen J, Chen L, et al. Overexpression miR-486-3p promoted by allicin enhances temozolomide sensitivity in glioblastoma via targeting MGMT. Neuromolecular Med. 2020;22(3):359–69.CrossRefPubMedPubMedCentral
53.
Yang H, Huang Y, He J, Chai G, Di Y, Wang A, et al. MiR-486–3p inhibits the proliferation, migration and invasion of retinoblastoma cells by targeting ECM1. Biosci Rep. 2020;40(6):BSR20200392.CrossRefPubMedPubMedCentral
54.
Ye H, Yu X, Xia J, Tang X, Tang L, Chen F. MiR-486-3p targeting ECM1 represses cell proliferation and metastasis in cervical cancer. Biomed Pharmacother. 2016;80:109–14.CrossRefPubMed
55.
Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, et al. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis. 2020;11(4):250.CrossRefPubMedPubMedCentral
56.
Lopez-Bertoni H, Kotchetkov IS, Mihelson N, Lal B, Rui Y, Ames H, et al. A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks. Cancer Res. 2020;80(8):1644–55.CrossRefPubMedPubMedCentral
57.
Niu C, Wang S, Guo J, Wei X, Jia M, Chen Z, et al. BACH1 recruits NANOG and histone H3 lysine 4 methyltransferase MLL/SET1 complexes to regulate enhancer-promoter activity and maintains pluripotency. Nucleic Acids Res. 2021;49(4):1972–86.CrossRefPubMedPubMedCentral
58.
Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, et al. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro Oncol. 2022;24(9):1471–81.CrossRefPubMedPubMedCentral
59.
Verdugo E, Puerto I, Medina MA. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun (Lond). 2022;42(11):1083–111.CrossRefPubMed
Metadata
Title
LINC00606 promotes glioblastoma progression through sponge miR-486-3p and interaction with ATP11B
Authors
Naijun Dong
Wenxin Qi
Lingling Wu
Jie Li
Xueqi Zhang
Hao Wu
Wen Zhang
Jiawen Jiang
Shibo Zhang
Wenjun Fu
Qian Liu
Guandong Qi
Lukai Wang
Yanyuan Lu
Jingyi Luo
Yanyan Kong
Yihao Liu
Robert Chunhua Zhao
Jiao Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-03058-z

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue

Research

HERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis

Research

PHB2 promotes SHIP2 ubiquitination via the E3 ligase NEDD4 to regulate AKT signaling in gastric cancer

Research

KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation

Research

The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

Research

Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside

Research

ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits